{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:19:05Z","timestamp":1791494345709,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40256-024-00713-w","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T09:51:35Z","timestamp":1735638695000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat"],"prefix":"10.1007","volume":"25","author":[{"given":"Jessica","family":"Huston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dontia","family":"Orey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Berner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Bisharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-4888","authenticated-orcid":false,"given":"Rebecca F.","family":"Goldfaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"713_CR1","first-page":"1","volume":"364","author":"Y Ostchega","year":"2020","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018. NCHS Data Brief. 2020;364:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"713_CR2","doi-asserted-by":"publisher","unstructured":"Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors [published correction appears in PLoS Med. 2011 Jan;8(1). https:\/\/doi.org\/10.1371\/annotation\/0ef47acd-9dcc-4296-a897-872d182cde57]. PLoS Med. 2009;6(4):e1000058. https:\/\/doi.org\/10.1371\/journal.pmed.1000058","DOI":"10.1371\/annotation\/0ef47acd-9dcc-4296-a897-872d182cde57 10.1371\/journal.pmed.1000058"},{"issue":"13","key":"713_CR3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jacc.2014.06.001","volume":"64","author":"AK Jacobs","year":"2014","unstructured":"Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC\/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(13):1373\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.001.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"713_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","volume":"34","author":"C Thomopoulos","year":"2016","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613\u201322. https:\/\/doi.org\/10.1097\/HJH.0000000000000881.","journal-title":"J Hypertens"},{"issue":"23","key":"713_CR5","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2020.04.038","volume":"75","author":"C Wang","year":"2020","unstructured":"Wang C, Yuan Y, Zheng M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.038.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"713_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","volume":"328","author":"RM Carey","year":"2022","unstructured":"Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328(18):1849\u201361. https:\/\/doi.org\/10.1001\/jama.2022.19590.","journal-title":"JAMA"},{"key":"713_CR7","doi-asserted-by":"publisher","unstructured":"Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension\u2013its identification and epidemiology [published correction appears in Nat Rev Nephrol. 2013 Sep;9(9):492]. Nat Rev Nephrol. 2013;9(1):51\u20138. https:\/\/doi.org\/10.1038\/nrneph.2012.260","DOI":"10.1038\/nrneph.2012.260"},{"key":"713_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1751-7176.2011.00445.x","volume":"13","author":"PA Sarafidis","year":"2011","unstructured":"Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens. 2011;13:523\u20138. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00445.x.","journal-title":"J Clin Hypertens"},{"issue":"11","key":"713_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1345\/aph.1P338","volume":"44","author":"JC Marrs","year":"2010","unstructured":"Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother. 2010;44(11):1762\u20139. https:\/\/doi.org\/10.1345\/aph.1P338.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"713_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108\u201318. https:\/\/doi.org\/10.1038\/s41440-022-01070-4.","journal-title":"Hypertens Res"},{"issue":"1\u20134","key":"713_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1152\/advan.00051.2001","volume":"26","author":"RE Booth","year":"2002","unstructured":"Booth RE, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ. 2002;26(1\u20134):8\u201320. https:\/\/doi.org\/10.1152\/advan.00051.2001.","journal-title":"Adv Physiol Educ"},{"issue":"5","key":"713_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"issue":"11","key":"713_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/13543784.2023.2276755","volume":"32","author":"A Awosika","year":"2023","unstructured":"Awosika A, Cho Y, Bose U, Omole AE, Adabanya U. Evaluating phase II results of baxdrostat, an aldosterone synthase inhibitor for hypertension. Expert Opin Investig Drugs. 2023;32(11):985\u201395. https:\/\/doi.org\/10.1080\/13543784.2023.2276755.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"713_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function. Clin Pharmacol Drug Dev. 2024;13(4):410\u20138. https:\/\/doi.org\/10.1002\/cpdd.1371.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"713_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40256-023-00572-x","volume":"23","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, et al. Results from a randomized, open-label, crossover study evaluating the effect of the aldosterone synthase inhibitor baxdrostat on the pharmacokinetics of metformin in healthy human subjects. Am J Cardiovasc Drugs. 2023;23:277\u201386. https:\/\/doi.org\/10.1007\/s40256-023-00572-x.","journal-title":"Am J Cardiovasc Drugs"},{"key":"713_CR16","unstructured":"Bhatt DL, Halvorsen YD, Marshall W, et al. HALO: results from a phase 3, double-blind, placebo-controlled trial evaluating the efficacy and safety of baxdrostat in patients with uncontrolled hypertension. Presented at: 72nd American College of Cardiology Scientific Sessions together with World Congress of Cardiology; New Orleans, LA; March 4-6, 2023. Abstract 23-LBCT-20864."},{"key":"713_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000595","author":"S Dey","year":"2023","unstructured":"Dey S, Frishman WH, Aronow WS. Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension. Cardiol Rev. 2023. https:\/\/doi.org\/10.1097\/CRD.0000000000000595. (Published online August 7, 2023).","journal-title":"Cardiol Rev"},{"key":"713_CR18","unstructured":"A Study of CIN-107 in Patients with Uncontrolled Hypertension (HALO). https:\/\/clinicaltrials.gov\/study\/NCT05137002?term=HALO&intr=baxdrostat&rank=1&tab=results. Retrieved Aug 8, 2024."},{"key":"713_CR19","unstructured":"Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124. https:\/\/clinicaltrials.gov\/study\/NCT05459688?intr=cin-107&rank=1. Retrieved Aug 8, 2024."},{"key":"713_CR20","unstructured":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxHTN). https:\/\/clinicaltrials.gov\/study\/NCT06034743?term=baxhtn&intr=baxdrostat&rank=1. Retrieved Aug 8, 2024."},{"key":"713_CR21","unstructured":"A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension (Bax24). https:\/\/clinicaltrials.gov\/study\/NCT06168409?rank=. Retrieved Aug 8, 2024."},{"key":"713_CR22","unstructured":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. https:\/\/clinicaltrials.gov\/study\/NCT06268873?intr=baxdrostat&rank=10. Retrieved Aug 8, 2024."},{"key":"713_CR23","unstructured":"Caffrey M. Halo misses end point, but optimism remains for Baxdrostat in resistant hypertension. AJMC. 2023. Accessed Aug 9, 2024. https:\/\/www.ajmc.com\/view\/halo-misses-end-point-but-optimism-remains-for-baxdrostat-in-resistant-hypertension."},{"key":"713_CR24","doi-asserted-by":"publisher","unstructured":"Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly\nselective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension.\n2017;69(1):189\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07716","DOI":"10.1161\/HYPERTENSIONAHA.116.07716"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00713-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:14:36Z","timestamp":1745324076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00713-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00713-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"5 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.H., D.O., A.K., Andrea.A., Andrew.A., J.B., Y.A., D.S., W.D., M.B., and R.F.G. declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Data sharing are not applicable to this article as no datasets were generated.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"J.H. was involved in supervision, data curation, analysis, reviewing, editing, and writing; D.O. was involved in data curation, analysis, and writing; A.K. was involved in data curation, analysis, and writing; Andrea.A. was involved in data curation, writing, and analysis; Andrew.A. was involved in data curation, analysis, and writing; J.B. was involved in reviewing and editing; Y.A. was involved in reviewing and editing; D.S. was involved in reviewing and editing; W.D. was involved in reviewing and editing; M.B. was involved in reviewing and editing; R.F.G. was involved in the conceptualization, project administration, reviewing, and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}